Acquisition Completed
Leyden Labs acquisition of RIGImmune
Advisers
RIGImmune
Target
- Legal adviser
Leyden Labs
Acquirer
Not disclosed
- Target
- RIGImmune
- Acquirer
- Leyden Labs
- Target based in
- United States (unverified)
- Buyer based in
- Netherlands (unverified)
- Completed
- 9 Sep 2026
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Novo Nordisk stake in Orbis Medicines Sep 2026 · Biotech
- Eli Lilly and Company acquisition of Merida Biosciences Aug 2026 · US$2.9bn · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
Sources
- 9 Sep 2026 Leyden Labs Acquires RIGImmune gunder.com